Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
The author was motivated to write this important book because currently there is no systematically-written document on the ZIKV disease, which could serve at this crucial moment as a textbook for medical students, physicians, nurses, and other healthcare providers as well as a reference book for basic researchers, professors, and the general public. The original concept of ZIKV-Charnolopathy due to compromised mitochondrial bioenergetics in highly vulnerable (neural progenitor cells, spermatocytes, oocytes etc.) cells and its amelioration by physiological and/or pharmacological interventions is based on years of research experience. This book describes unique organ and disease-specific Charnoly body (CB) inhibitors, charnolophagy inducers, CB sequestration inhibitors, and chanolophagosome stabilisers as promising charnolopharmacotherapeutics. They are meant to aid in the prevention and treatment of the ZIKV-linked diversified spectrum of neurodevelopmental anomalies (embryopathies) in newborn infants and Guillain Barre Syndrome (GBS) in adults. Clinical management of ZIKV-induced GBS employing IV immunoglobulin and plasmapheresis (plasma exchange) is also described.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
The author was motivated to write this important book because currently there is no systematically-written document on the ZIKV disease, which could serve at this crucial moment as a textbook for medical students, physicians, nurses, and other healthcare providers as well as a reference book for basic researchers, professors, and the general public. The original concept of ZIKV-Charnolopathy due to compromised mitochondrial bioenergetics in highly vulnerable (neural progenitor cells, spermatocytes, oocytes etc.) cells and its amelioration by physiological and/or pharmacological interventions is based on years of research experience. This book describes unique organ and disease-specific Charnoly body (CB) inhibitors, charnolophagy inducers, CB sequestration inhibitors, and chanolophagosome stabilisers as promising charnolopharmacotherapeutics. They are meant to aid in the prevention and treatment of the ZIKV-linked diversified spectrum of neurodevelopmental anomalies (embryopathies) in newborn infants and Guillain Barre Syndrome (GBS) in adults. Clinical management of ZIKV-induced GBS employing IV immunoglobulin and plasmapheresis (plasma exchange) is also described.